🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨New publication out in The Lancet Global Health from us supporting increasingly complex decisions to list new cancer medicines on World Health Organization (WHO) Essential Medicines List. 👇🏼 We shed light on processes, challenges, and a way forward #globaloncology thelancet.com/journals/langl…

From 2000-2021, manufacturers earned $111 billion on brand-name #inhalers in the US AFTER patents on their active ingredients had expired. How? By patenting other aspects of the products (e.g., delivery devices). New piece out in JAMA jamanetwork.com/journals/jama/… 🧵

High drug prices are not justified by industry’s research and development spending, argue @Aris_Angelis and colleagues. From 1999 to 2018, the world’s 15 largest biopharmaceutical companies spent more on selling, general, and admin activities than on R&D bmj.com/content/380/bm…

Are high drug prices justified? In our The BMJ Analysis we investigate the spending of the 15 largest biopharmaceutical companies over 20 years and review available evidence on the added therapeutic benefit of new medicines. Olivier Wouters Els Torreele @mckee Global Health Economics Centre

Fascinating deep dive into the AstraZeneca-Fiocruz partnership that saw Brazil produce millions of doses of the AZ vaccine. Offers lots of insights into vaccine technology transfer Elize Massard, Ken Shadlen (LSE International Development) and Helena Moraes Achcar (FGV EAESP) sciencedirect.com/science/articl…

In new JAMA Health Forum paper, LSE Health Policy’s Huseyin Naci and Robin Forrest examine the insurer restrictions on new drugs in the US Medicare program➡️bit.ly/3kqCJdT Aaron Kesselheim Program On Regulation, Therapeutics, And Law

Want to learn more about pharmaceutical policy and economics? In a new report commissioned by The Health Foundation #REAL Centre, the Department’s Huseyin Naci & Robin Forrest explain pharmaceutical discovery, development, approval and adoption. ➡️ Access here: bit.ly/41FbIUU

Regulated information sources for anticancer drugs in Europe fail to address the information needs of patients, finds study. If patients lack access to such information, clinical decisions may not align with their preferences and needs, warn researchers bmj.com/content/380/bm…

In our new publication at Research Policy with Albert Banal-Estanol, M Jofre-Bonet, Giulia Iori, Michele Tumminello and Pietro Vassallo, we evaluate the incremental impact of the Research Excellence Framework (REF) 2014 in the fields of Economics and Business.1/5 sciencedirect.com/science/articl…

🚨New The Lancet Oncology research was published right before #ASCO23 with a team of talented co-authors from around the 🌏, led by myself and Bishal Gyawali, MD, PhD, FASCO My post #ASCO2023 🧵👇 thelancet.com/journals/lanon…

New piece: Drugs increasingly approved for many indications. Findings indicate substantially lower R&D costs for supplemental indications compared to first indications. More public data necessary to validate findings. with Olivier Wouters LSE Health Policy jamanetwork.com/journals/jama-…

Thanks to Olivier Wouters for visiting CEVR and a truly excellent presentation on drug R&D expenditures, #HTA policies, & drug #patents. Brown University School of Public Health Program On Regulation, Therapeutics, And Law UW School of Pharmacy @LSE Inmaculada (Inma) Hernández